Brief: Zentalis Pharmaceuticals Q2 EPS USD -0.37

Zentalis Pharmaceuticals

06/08/2025 21:05

Overview

Zentalis Q2 operating expenses decreased to $36.1 mln from $65.1 mln last year

Company maintains $303.4 mln cash position, supporting operations into late 2027

DENALI Phase 2 trial on track, topline data expected by year-end 2026

Outlook

Company expects topline data from DENALI trial by end of 2026

Zentalis has cash runway into late 2027

DENALI trial could support accelerated approval, pending FDA feedback

Company focused on late-stage development of azenosertib

Result Drivers

STRATEGIC RESTRUCTURING - Completed restructuring prioritizes late-stage development of azenosertib, reducing operating expenses and extending cash runway into late 2027

CLINICAL DEVELOPMENT - Continued focus on advancing azenosertib in Cyclin E1-positive PROC patients, with DENALI Phase 2 trial on track for topline data by year-end 2026

EXPENSE REDUCTION - Significant decrease in R&D expenses due to reduced clinical, lab, and drug manufacturing costs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 EPS
-$0.37
Q2 Net Income
-$26.87 mln
Q2 Operating Expenses
$36.06 mln
Q2 Operating Income
-$36.06 mln
Q2 Pretax Profit
-$26.87 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Zentalis Pharmaceuticals Inc is $6.00, about 76.5% above its August 5 closing price of $1.41

Press Release: ID:nGNX24nzsn

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)